🟢 Gilead Sciences is trading 4% up today after EU backing for Trodelvy combo

Gilead Sciences is trading 4% up at ARS 53,725 following a positive regulatory recommendation from the European Medicines Agency (EMA).

• The EMA’s CHMP issued a favorable opinion for Trodelvy in combination with Merck’s Keytruda for the treatment of metastatic triple‑negative breast cancer.
• This regulatory milestone strengthens Gilead's oncology pipeline in a key therapeutic area, significantly boosting investor confidence.
• The stock's upward movement is further supported by a broader rally across the biotechnology sector.